

Procter & Gamble Hygiene and Health Care Limited CIN: 124239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakkala Antheri (E), Mumbai 400 099 Tel: (91 – 22) 6958 6000 Fax: (91 – 22) 6958 7337 Website: in.pq.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2024

(₹ in Lakhs)

					( : III Zaitilo)
		(1)	(2)	(3)	(4)
			Preceding	Corresponding	Previous
	Particulars	Three Months	Three Months	Three Months	Year
		Ended	Ended	Ended	Ended
L		30th Sept 2024	30th June 2024	30th Sept 2023	30th June 2024
		(Unaudited)	(Audited) Refer note 6	(Unaudited)	(Audited)
Г					
1	Income				
	Sale of products	1 13 273	92 743	1 13 506	4 19 157
	Other operating revenues	243	432	329	1 413
2	Revenue from operations	1 13 516	93 175	1 13 835	4 20 570
3	Other income	850	731	1 577	5 225
	Total income (2+3)	1 14 366	93 906	1 15 412	4 25 795
4	Expenses				
a)	Cost of raw and packing materials consumed	19 400	17 685	21 652	77 194
b)	Purchases of stock-in-trade (Traded goods)	21 682	23 180	22 285	85 438
c)	Changes in inventories of finished goods, work-in-progress and stock-in- trade	1 041	( 2830)	574	( 1213)
d)	Employee benefits expense	6 051	6 713	6 372	24 564
e)	Finance costs	191	( 3)	194	2 699
f)	Depreciation and amortization expense	1 170	1 340	1 430	5 650
g)	Impairment losses (Refer Note 3)		1 303		1 303
g)	Advertising & sales promotion expenses	17 294	15 366	15 342	56 776
h)	Other expenses	19 000	19 924	19 116	79 464
	Total expenses	85 829	82 678	86 965	3 31 875
5	Profit before tax (2+3-4)	28 537	11 228	28 447	93 920
6	Tax expense				
a)	Current tax	7 995	3 292	7 533	25 955
b)	Deferred tax				
		( 648)	( 167)	( 155)	, ,
c)	Prior year tax adjustments		( 3)	`	( 1 586) 2 049
ľ	Prior year tax adjustments	7 347	( 3) 3 122	7 378	2 049 26 418
7			( 3)	`	2 049
ľ	Prior year tax adjustments	7 347	( 3) 3 122	7 378	2 049 26 418
7	Prior year tax adjustments  Profit for the period (5-6)	7 347	( 3) 3 122	7 378	2 049 26 418
7	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income	7 347	( 3) 3 122	7 378	2 049 26 418
7	Prior year tax adjustments  Profit for the period (5-6)  Other comprehensive income  Items that will not be reclassified to profit or loss:	7 347 21 190 185 ( 46)	( 3) 3 122 8 106 ( 186) 47	7 378 21 069 ( 250) 63	2 049 26 418 67 502 738 ( 186)
7	Prior year tax adjustments  Profit for the period (5-6)  Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans	7 347 21 190	( 3) 3 122 8 106	7 378 21 069 ( 250)	2 049 26 418 67 502
7	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above	7 347 21 190 185 ( 46)	( 3) 3 122 8 106 ( 186) 47	7 378 21 069 ( 250) 63	2 049 26 418 67 502 738 ( 186)
7 8	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above Total other comprehensive income for the period	7 347 21 190 185 ( 46) 139	( 3) 3 122 8 106 ( 186) 47 ( 139)	7 378 21 069 ( 250) 63 ( 187)	2 049 26 418 67 502 738 ( 186) 552
7 8	Prior year tax adjustments  Profit for the period (5-6)  Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above  Total other comprehensive income for the period Total comprehensive income for the period (7+8)	7 347 21 190 185 ( 46) 139 21 329	( 3) 3 122 8 106 ( 186) 47 ( 139) 7 967	7 378 21 069 ( 250) 63 ( 187) 20 882	2 049 26 418 67 502 738 ( 186) 552 68 054
7 8 9 10	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above Total other comprehensive income for the period Total comprehensive income for the period (7+8) Paid-up equity share capital (Face Value ₹ 10 per equity share) Other Equity Earnings per Share (Face value of ₹ 10 per equity share) (not	7 347 21 190 185 ( 46) 139 21 329 3 246	( 3) 3 122 8 106 ( 186) 47 ( 139) 7 967	7 378 21 069 ( 250) 63 ( 187) 20 882	2 049 26 418 67 502 738 ( 186) 552 68 054 3 246
7 8 9 10 11	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above Total other comprehensive income for the period Total comprehensive income for the period (7+8) Paid-up equity share capital (Face Value ₹ 10 per equity share) Other Equity	7 347 21 190 185 ( 46) 139 21 329 3 246	( 3) 3 122 8 106 ( 186) 47 ( 139) 7 967	7 378 21 069 ( 250) 63 ( 187) 20 882	2 049 26 418 67 502 738 ( 186) 552 68 054 3 246
7 8 9 10 11	Prior year tax adjustments  Profit for the period (5-6) Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit plans Income tax effect on above Total other comprehensive income for the period Total comprehensive income for the period (7+8) Paid-up equity share capital (Face Value ₹ 10 per equity share) Other Equity Earnings per Share (Face value of ₹ 10 per equity share) (not annualised):	7 347 21 190 185 ( 46) 139 21 329 3 246	( 186) 47 ( 139) 7 967 3 246	7 378 21 069 ( 250) 63 ( 187) 20 882 3 246	2 049 26 418 67 502 738 ( 186) 552 68 054 3 246 74 240

## Notes

- 1 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 30th October, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as appropriet.
- 2 During the previous year, the Company had arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the years ended March 2011 to March 2019. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 656 lakhs, and interest amounting to ₹ 1 944 lakhs, has been accounted as Prior Period Tax Adjustments and Finance Costs respectively in the previous year.
- 3 During the previous year, certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at 30th June, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, had been tested for impairment and a loss amounting to ₹ 1 303 lakhs has been recognized in the financial results for the quarter and year ended 30th June, 2024.
- 4 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 Operating Segments. Accordingly, no separate segment information has been provided.
- 5 The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- 6 The figures for the preceding three months ended 30th June, 2024 are the balancing figures between the audited figures in respect of the full financial year ended 30th June, 2024 and the year to date figures upto the third quarter of that financial year.
- 7 The Company does not have a subsidiary, associate or a joint venture as at 30th September, 2024

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited

Place: Mumbai Date: October 30, 2024 Kumar Venkatasubramanian Managing Director